 | • レポートコード：MRC23Q36260 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のピーナッツアレルギー治療薬市場について調査・分析し、世界のピーナッツアレルギー治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（エピネフリン注射、抗ヒスタミン薬、経口免疫療法、その他）、用途別セグメント分析（病院薬局、小売店薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Mylan、Bayer、UCB Pharma、J & J、Perrigo、GSK、Kaleo、Amneal Pharma、ALK Abello、Aimmune Therapeutics、HUAPONT Pharm、Allergy Therapeutics、ASIT Biotech、Sanofi、DBV Technologies、HAL Allergy、Intrommune Therapeuticsなどが含まれています。世界のピーナッツアレルギー治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ピーナッツアレルギー治療薬市場規模を推定する際に考慮しました。本レポートは、ピーナッツアレルギー治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ピーナッツアレルギー治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・ピーナッツアレルギー治療薬市場の概要 - ピーナッツアレルギー治療薬のタイプ別セグメント - 世界のピーナッツアレルギー治療薬市場規模：タイプ別分析（エピネフリン注射、抗ヒスタミン薬、経口免疫療法、その他） - ピーナッツアレルギー治療薬の用途別セグメント - 世界のピーナッツアレルギー治療薬市場規模：用途別分析（病院薬局、小売店薬局、その他） - 世界のピーナッツアレルギー治療薬市場規模予測（2018年-2029年） ・ピーナッツアレルギー治療薬市場の成長トレンド - ピーナッツアレルギー治療薬の地域別市場規模（2018年-2029年） - ピーナッツアレルギー治療薬市場ダイナミクス - ピーナッツアレルギー治療薬の業界動向 - ピーナッツアレルギー治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：エピネフリン注射、抗ヒスタミン薬、経口免疫療法、その他 - 世界のピーナッツアレルギー治療薬のタイプ別市場規模（2018年-2023年） - 世界のピーナッツアレルギー治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院薬局、小売店薬局、その他 - 世界のピーナッツアレルギー治療薬の用途別市場規模（2018年-2023年） - 世界のピーナッツアレルギー治療薬の用途別市場規模（2024年-2029年） ・ピーナッツアレルギー治療薬の地域別市場規模 - 北米のピーナッツアレルギー治療薬市場規模（2018年-2029年） - アメリカのピーナッツアレルギー治療薬市場規模（2018年-2029年） - ヨーロッパのピーナッツアレルギー治療薬市場規模（2018年-2029年） - アジア太平洋のピーナッツアレルギー治療薬市場規模（2018年-2029年） - 中国のピーナッツアレルギー治療薬市場規模（2018年-2029年） - 日本のピーナッツアレルギー治療薬市場規模（2018年-2029年） - 韓国のピーナッツアレルギー治療薬市場規模（2018年-2029年） - インドのピーナッツアレルギー治療薬市場規模（2018年-2029年） - オーストラリアのピーナッツアレルギー治療薬市場規模（2018年-2029年） - 中南米のピーナッツアレルギー治療薬市場規模（2018年-2029年） - 中東・アフリカのピーナッツアレルギー治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Mylan、Bayer、UCB Pharma、J & J、Perrigo、GSK、Kaleo、Amneal Pharma、ALK Abello、Aimmune Therapeutics、HUAPONT Pharm、Allergy Therapeutics、ASIT Biotech、Sanofi、DBV Technologies、HAL Allergy、Intrommune Therapeutics ・アナリストの観点/結論 ・調査方法とデータソース |
Peanuts are one of the food allergens most commonly associated with anaphylaxis, a sudden and potentially deadly condition that requires immediate attention and treatment.
Highlights
The global Peanut Allergy Therapeutics market was valued at US$ 953.7 million in 2022 and is anticipated to reach US$ 6416.9 million by 2029, witnessing a CAGR of 37.4% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
United States is the largest consumption place, with a consumption market share nearly 45% in 2019. Following United States, Europe is the second largest consumption place with the consumption market share of 31%.
Market competition is intense. Mylan, Bayer, UCB Pharma, J & J, Perrigo,top 5 players took 52% market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peanut Allergy Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peanut Allergy Therapeutics.
The Peanut Allergy Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Peanut Allergy Therapeutics market comprehensively. Regional market sizes, concerning products by type, by distribution channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peanut Allergy Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by distribution channel, and by regions.
By Company
Mylan
Bayer
UCB Pharma
J & J
Perrigo
GSK
Kaleo
Amneal Pharma
ALK Abello
Aimmune Therapeutics
HUAPONT Pharm
Allergy Therapeutics
ASIT Biotech
Sanofi
DBV Technologies
HAL Allergy
Intrommune Therapeutics
Segment by Type
Epinephrine Injection
Antihistamines
Oral Immunotherapy
Other
Segment by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, distribution channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peanut Allergy Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by distribution channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peanut Allergy Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Epinephrine Injection
1.2.3 Antihistamines
1.2.4 Oral Immunotherapy
1.2.5 Other
1.3 Market by Distribution Channel
1.3.1 Global Peanut Allergy Therapeutics Market Growth by Distribution Channel: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peanut Allergy Therapeutics Market Perspective (2018-2029)
2.2 Peanut Allergy Therapeutics Growth Trends by Region
2.2.1 Global Peanut Allergy Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Peanut Allergy Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Peanut Allergy Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Peanut Allergy Therapeutics Market Dynamics
2.3.1 Peanut Allergy Therapeutics Industry Trends
2.3.2 Peanut Allergy Therapeutics Market Drivers
2.3.3 Peanut Allergy Therapeutics Market Challenges
2.3.4 Peanut Allergy Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peanut Allergy Therapeutics Players by Revenue
3.1.1 Global Top Peanut Allergy Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Peanut Allergy Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Peanut Allergy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peanut Allergy Therapeutics Revenue
3.4 Global Peanut Allergy Therapeutics Market Concentration Ratio
3.4.1 Global Peanut Allergy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peanut Allergy Therapeutics Revenue in 2022
3.5 Peanut Allergy Therapeutics Key Players Head office and Area Served
3.6 Key Players Peanut Allergy Therapeutics Product Solution and Service
3.7 Date of Enter into Peanut Allergy Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peanut Allergy Therapeutics Breakdown Data by Type
4.1 Global Peanut Allergy Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Peanut Allergy Therapeutics Forecasted Market Size by Type (2024-2029)
5 Peanut Allergy Therapeutics Breakdown Data by Distribution Channel
5.1 Global Peanut Allergy Therapeutics Historic Market Size by Distribution Channel (2018-2023)
5.2 Global Peanut Allergy Therapeutics Forecasted Market Size by Distribution Channel (2024-2029)
6 North America
6.1 North America Peanut Allergy Therapeutics Market Size (2018-2029)
6.2 North America Peanut Allergy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Peanut Allergy Therapeutics Market Size by Country (2018-2023)
6.4 North America Peanut Allergy Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peanut Allergy Therapeutics Market Size (2018-2029)
7.2 Europe Peanut Allergy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Peanut Allergy Therapeutics Market Size by Country (2018-2023)
7.4 Europe Peanut Allergy Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peanut Allergy Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Peanut Allergy Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Peanut Allergy Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Peanut Allergy Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peanut Allergy Therapeutics Market Size (2018-2029)
9.2 Latin America Peanut Allergy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Peanut Allergy Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Peanut Allergy Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peanut Allergy Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Peanut Allergy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Peanut Allergy Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Peanut Allergy Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mylan
11.1.1 Mylan Company Detail
11.1.2 Mylan Business Overview
11.1.3 Mylan Peanut Allergy Therapeutics Introduction
11.1.4 Mylan Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.1.5 Mylan Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Peanut Allergy Therapeutics Introduction
11.2.4 Bayer Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.2.5 Bayer Recent Development
11.3 UCB Pharma
11.3.1 UCB Pharma Company Detail
11.3.2 UCB Pharma Business Overview
11.3.3 UCB Pharma Peanut Allergy Therapeutics Introduction
11.3.4 UCB Pharma Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.3.5 UCB Pharma Recent Development
11.4 J & J
11.4.1 J & J Company Detail
11.4.2 J & J Business Overview
11.4.3 J & J Peanut Allergy Therapeutics Introduction
11.4.4 J & J Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.4.5 J & J Recent Development
11.5 Perrigo
11.5.1 Perrigo Company Detail
11.5.2 Perrigo Business Overview
11.5.3 Perrigo Peanut Allergy Therapeutics Introduction
11.5.4 Perrigo Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.5.5 Perrigo Recent Development
11.6 GSK
11.6.1 GSK Company Detail
11.6.2 GSK Business Overview
11.6.3 GSK Peanut Allergy Therapeutics Introduction
11.6.4 GSK Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.6.5 GSK Recent Development
11.7 Kaleo
11.7.1 Kaleo Company Detail
11.7.2 Kaleo Business Overview
11.7.3 Kaleo Peanut Allergy Therapeutics Introduction
11.7.4 Kaleo Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.7.5 Kaleo Recent Development
11.8 Amneal Pharma
11.8.1 Amneal Pharma Company Detail
11.8.2 Amneal Pharma Business Overview
11.8.3 Amneal Pharma Peanut Allergy Therapeutics Introduction
11.8.4 Amneal Pharma Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.8.5 Amneal Pharma Recent Development
11.9 ALK Abello
11.9.1 ALK Abello Company Detail
11.9.2 ALK Abello Business Overview
11.9.3 ALK Abello Peanut Allergy Therapeutics Introduction
11.9.4 ALK Abello Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.9.5 ALK Abello Recent Development
11.10 Aimmune Therapeutics
11.10.1 Aimmune Therapeutics Company Detail
11.10.2 Aimmune Therapeutics Business Overview
11.10.3 Aimmune Therapeutics Peanut Allergy Therapeutics Introduction
11.10.4 Aimmune Therapeutics Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.10.5 Aimmune Therapeutics Recent Development
11.11 HUAPONT Pharm
11.11.1 HUAPONT Pharm Company Detail
11.11.2 HUAPONT Pharm Business Overview
11.11.3 HUAPONT Pharm Peanut Allergy Therapeutics Introduction
11.11.4 HUAPONT Pharm Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.11.5 HUAPONT Pharm Recent Development
11.12 Allergy Therapeutics
11.12.1 Allergy Therapeutics Company Detail
11.12.2 Allergy Therapeutics Business Overview
11.12.3 Allergy Therapeutics Peanut Allergy Therapeutics Introduction
11.12.4 Allergy Therapeutics Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.12.5 Allergy Therapeutics Recent Development
11.13 ASIT Biotech
11.13.1 ASIT Biotech Company Detail
11.13.2 ASIT Biotech Business Overview
11.13.3 ASIT Biotech Peanut Allergy Therapeutics Introduction
11.13.4 ASIT Biotech Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.13.5 ASIT Biotech Recent Development
11.14 Sanofi
11.14.1 Sanofi Company Detail
11.14.2 Sanofi Business Overview
11.14.3 Sanofi Peanut Allergy Therapeutics Introduction
11.14.4 Sanofi Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.14.5 Sanofi Recent Development
11.15 DBV Technologies
11.15.1 DBV Technologies Company Detail
11.15.2 DBV Technologies Business Overview
11.15.3 DBV Technologies Peanut Allergy Therapeutics Introduction
11.15.4 DBV Technologies Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.15.5 DBV Technologies Recent Development
11.16 HAL Allergy
11.16.1 HAL Allergy Company Detail
11.16.2 HAL Allergy Business Overview
11.16.3 HAL Allergy Peanut Allergy Therapeutics Introduction
11.16.4 HAL Allergy Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.16.5 HAL Allergy Recent Development
11.17 Intrommune Therapeutics
11.17.1 Intrommune Therapeutics Company Detail
11.17.2 Intrommune Therapeutics Business Overview
11.17.3 Intrommune Therapeutics Peanut Allergy Therapeutics Introduction
11.17.4 Intrommune Therapeutics Revenue in Peanut Allergy Therapeutics Business (2018-2023)
11.17.5 Intrommune Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details